Crossref
What is the optimal dose of tyrosine kinase inhibitors in chronic myeloid leukaemia?
Transfuze a hematologie dnes · 2021
DOI: 10.48095/cctahd202128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfuze a hematologie dnes, 2021. Verfasst von Daniela Žáčková und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Žáčková, D., Čičátková, P., Kvetková, A., Horňák, T., Semerád, L., & Mayer, J. (2021). What is the optimal dose of tyrosine kinase inhibitors in chronic myeloid leukaemia?. Transfuze a hematologie dnes. https://doi.org/10.48095/cctahd202128
Vancouver
Žáčková D, Čičátková P, Kvetková A, Horňák T, Semerád L, Mayer J. What is the optimal dose of tyrosine kinase inhibitors in chronic myeloid leukaemia?. Transfuze a hematologie dnes. 2021. doi:10.48095/cctahd202128
BibTeX
@article{kov2021,
author = {Žáčková, Daniela and Čičátková, Petra and Kvetková, Anežka and Horňák, Tomáš and Semerád, Lukáš and Mayer, Jiří},
title = {What is the optimal dose of tyrosine kinase inhibitors in chronic myeloid leukaemia?},
journal = {Transfuze a hematologie dnes},
year = {2021},
doi = {10.48095/cctahd202128}
}
EUVIMED